Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)

Together, these studies support the use of pdFX for on-demand treatment of bleeding, routine prophylaxis, and perioperative management of bleeding in patients with HFXD.

Keyphrases

endothelial cells
atrial fibrillation
replacement therapy
acute kidney injury